Audit: QRS - Semaglutide for Health & Longevity
Audit conducted on 10/31/2026 12:17 using AI4L + evidence-mcp / Opus 5.5
Summary
| Items | Count |
|---|---|
| Total | 97 |
| Passed | 86 |
| Failed | 0 |
| N/A | 11 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every lede, protocol, time, gate, tier, marker and cadence entry traced to ER text (e.g., time subs to ER line 540, protocol to lines 504–509, gates to lines 445–478) |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Cautious phrasing kept on gate/protocol surfaces: “(no outcome trials)”, “(use has not been evaluated)”, “(inferred; no trial data)”, “(no human data)”, “judged not clinically relevant” |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening found; “benefit is uncertain” in lean adults mirrors ER Conclusion |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Facts stay in their ER categories; modifying factors not surfaced as gates or side effects |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | Only Wegovy, STEP 1, SELECT and Peter Attia appear, each tied to the same fact in the ER (lines 504–508, 540) |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s measured, evidence-based tone |
| 2.2 | The tone of the QRS is expert, accessible, objective, and data-driven | 🟢 | |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | |
| 2.6 | The QRS never addresses the reader directly — it presents evidence, not guidance | 🟢 | No second-person address; target wording in monitoring is carried from the ER table |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms present (NAION, MASH, HbA1c, hs-CRP, MEN 2) are ER labels or marker names |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | |
| 2.9 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | |
| 2.10 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | |
| 2.11 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | |
| 2.12 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Lede separates strong evidence in people with weight-related disease from uncertain benefit in lean, healthy adults |
| 2.13 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No “anti-aging” wording |
| 2.14 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | Formal terms used (prescription medication, injection, tablet, adverse events); no “pill” or “shot” |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why” |
🟢 | All fixed headings, gate headings, tier labels and column headers unchanged |
| 3.2 | Every element carrying a data-qrs-var attribute in [qrs_template] is present in the QRS with the same name | 🟢 | All template data-qrs-var names present; # rows expanded to marker_1–9 and qualitative_item_1–6 |
| 3.3 | Everything outside the data-qrs-var spans — markup, text, styles, comments — is as in the template; spans that no checklist item addresses are left unchanged as well | 🟢 | Diff against template shows changes only inside data-qrs-var spans, the metadata block and the risks_speculative hide attribute |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | An empty ER section never produces visible empty-state text in the QRS: the corresponding region is hidden or left empty. Phrases such as “None documented in human trials to date” or “Not formally studied” appear only where the ER uses them for a fact the QRS carries over. | 🟢 | Empty Speculative risk tier hidden (line 610); no empty-state text |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol and interaction labels use the ER bold labels verbatim (example lists trimmed only) |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Label trimming limited to dropping example names (e.g., glyburide, dulaglutide, losartan); words kept are the ER’s own |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji indicators |
| 4.5 | The QRS is designed to render on one A4 page. It fails this item only for one of four things: a trailing clause after a dash, an optional gloss, an example list left untrimmed, or a repetition. Nothing else is cut to fit. | 🟢 | No trailing dash clauses, optional glosses outside ER labels, untrimmed example lists or repetitions found |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Metadata comment is line 2, directly after <!doctype html> |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration is quoted, as its value contains a colon |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: semaglutide_2026-1031-0650_Opus_ER.md |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.10.25 matches QRS.md |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-1031-1154 |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus |
| 5.9 | The nickname of the AI is the full name without the version number, with all remaining words joined by hyphens (e.g., Opus, Sonnet, Grok, Gemini-Flash, GPT); when the full name has no version number or is “Unknown”, the nickname equals the full name | 🟢 | |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5.5 |
| 5.11 | The full name of the AI consists of the model name (the word or words directly before the version number, leaving out the first if there is more than one, e.g., Claude Opus 5.5 → Opus 5.5), the model version number and the variant (if any) as stated in the system prompt or developer instructions of the creating model, with every word capitalized and without product, effort or pricing names (e.g., Opus X.Y, Sonnet X.Y, Grok X.Y, Gemini X.Y Flash, GPT X.Y), the model name alone when the system prompt or developer instructions name a model without a version number (e.g., Grok), or “Unknown” when neither the system prompt nor the developer instructions of the creating model name a model | 🟢 | |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: semaglutide_2026-1031-0650_Opus_QRS.html |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Semaglutide for Health & Longevity - Quick Reference Sheet |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 10/31/2026 |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Opus 5.5 |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | Opens with “Semaglutide is a prescription medication for diabetes and weight loss” |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses the ER Conclusion: who benefits, uncertainty in lean adults, side effects, muscle loss, rebound |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | 70 words (script count) |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each fact maps to ER Motivation/Conclusion passages (lines 37, 598–602) |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All nine ER “Populations who should avoid” entries represented (lines 470–478) |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Rationales and citations stripped; remaining parentheticals are ER cautious qualifiers |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “within 2 months”, “Severe”, “below 18.5”, “during treatment” preserved |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation in its contraindications |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | Section populated; ER names populations to avoid |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | Section is not empty |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | |
| 9.2 | [caution_items] represent the ER’s documented interactions — the items under its “Documented interactions:” label — excluding any that are already listed as Contraindications and any entry phrased as no interaction found | 🟢 | Nine documented interactions carried; the three “No clinically relevant interaction found” entries (Warfarin/metformin/atorvastatin/digoxin, combined oral contraceptives, omeprazole/paracetamol) correctly excluded |
| 9.3 | [caution_theoretical_items] represent the ER’s theoretical interactions — the items under its “Theoretical interactions (inferred from mechanism, not studied in humans):” label | 🟢 | All seven ER theoretical interactions carried |
| 9.4 | The ER placeholder “None identified” is never an item: it means that group is empty | 🟢 | No “None identified” placeholder used |
| 9.5 | Individual [caution_items] and [caution_theoretical_items] are formatted as <li></li>. The template’s bold “Theoretical (inferred from mechanism)” sub-heading is the only marker of the second list’s status: no item carries “(theoretical)”, “inferred from” or a mechanism clause | 🟢 | All items in <li>; no “(theoretical)”, “inferred from” or mechanism clause |
| 9.6 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Mitigations, mechanisms and citations stripped |
| 9.7 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | At least one example drug kept in every ER parenthetical list |
| 9.8 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation in its interactions |
| 9.9 | If the ER’s theoretical group is empty, the whole Theoretical block — the caution_theoretical span with its sub-heading and list — is hidden with style="display:none", not removed: its spans stay in place, empty. |
N/A | The ER’s theoretical group is not empty |
| 9.10 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | Section populated; ER names interactions |
| 9.11 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on, and the Theoretical block is hidden per 9.9. E.g. | N/A | Section is not empty |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Therapeutic Protocol section |
🟢 | |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from that section | 🟢 | Injectable, oral and lower-dose longevity protocols chosen from ER Therapeutic Protocol |
| 10.3 | If fewer than three distinct actionable implementation aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing. |
N/A | The ER gives more than three actionable aspects |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from that section. | 🟢 |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Weight loss, cardiovascular benefit and appetite — the three time aspects in ER line 540 |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered weight loss, cardiovascular benefit (both High-tier), then appetite |
| 11.3 | If fewer than three distinct time-to-effect aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing. |
N/A | The ER gives three time-to-effect aspects |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | |
| 11.5 | If the ER provides no information on time to effect at all, the whole Time to effect block (its subhead and all three sets) is hidden with style="display:none", not removed: its spans stay in place, empty. |
N/A | The ER provides time-to-effect information |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Items reduced to ER headings without effect sizes or qualifiers (e.g., “Modest” dropped) |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content |
| 12.5 | If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing. |
N/A | All four benefit tiers have items |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | All 23 ER risks carried as concise headings |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | Parentheticals such as “(Optic-Nerve Stroke)”, “(Dysesthesia)”, “(Dysgeusia)” stripped |
| 13.5 | If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing. |
🟢 | Empty Speculative tier hidden with style=”display:none” (line 610) |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring Protocol & Defining Success section |
🟢 | |
| 14.2 | All measurable/quantifiable biomarkers from that section are listed, one table row per marker; the template’s # row is the pattern, repeated with # replaced by 1, 2, 3 … in the data-qrs-var names |
🟢 | All nine ER table biomarkers listed as marker_1–9 |
| 14.3 | [marker_#name] is the marker, [marker#target] its target value or range as given in the ER, [marker#_why] its purpose in a few words; a target the ER does not give is written “Not specified in the ER” | 🟢 | Targets match ER Optimal Functional Range column; purposes condensed from “Why Measure It?” |
| 14.4 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from that section. It is not left with placeholder text or empty. | 🟢 | Cadence taken from ER line 559 plus baseline (line 557) |
| 14.5 | If the ER names no measurable biomarker, the table is hidden with style="display:none" and the single # row is left as in the template |
N/A | The ER names measurable biomarkers |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring Protocol & Defining Success section |
🟢 | |
| 15.2 | All subjective/qualitative markers from that section are listed, one <li> per marker; the template’s # item is the pattern, repeated with # replaced by 1, 2, 3 … |
🟢 | All six ER qualitative markers listed as qualitative_item_1–6 |
| 15.3 | If the ER names no qualitative marker, the card’s list is hidden with style="display:none" and the single # item is left as in the template |
N/A | The ER names qualitative markers |
Issues 10/31/2026 12:17
Pass rate 100.00%. No issues found.
Issues 10/31/2026 12:14
- 2.5 / 2.6 — Imperative “avoid” in interaction: The Key Interactions item “Other GLP-1 receptor agonists or semaglutide products (liraglutide, tirzepatide)” at line 572 ends with the imperative “avoid”, which recommends and addresses the reader instead of presenting the ER fact that co-use is not recommended.
- 8.4 — Attribution in contraindication: The contraindication at line 555, “Prior pancreatitis (inferred from the label; no trial data)”, keeps the source attribution “from the label”.
Fixes 10/31/2026 12:14
- 2.5 / 2.6 — Imperative “avoid” replaced: Changed the GLP-1 receptor agonist interaction text from “avoid” to “co-use not recommended”, per the ER wording.
- 8.4 — Attribution removed: Changed “Prior pancreatitis (inferred from the label; no trial data)” to “Prior pancreatitis (inferred; no trial data)”.
Issues 10/31/2026 12:11
- 2.7 — Unnecessary jargon outside labels: The theoretical opioid item at line 582 uses “contribute to ileus” and the cadence at line 731 uses “during titration”, although the ER’s plain equivalents (“stalled bowel movement”, “dose escalation”) are available.
- 4.5 — Untrimmed example list: “Blood-pressure-lowering drugs (amlodipine, losartan)” at line 571 keeps both ER examples where one would do.
Fixes 10/31/2026 12:11
- 2.7 — Unnecessary jargon outside labels: Replaced “contribute to ileus” with “contribute to stalled bowel movement” in the theoretical opioid item, and “during titration” with “during dose escalation” in the monitoring cadence, using the ER’s own plain wording.
- 4.5 — Untrimmed example list: Trimmed “Blood-pressure-lowering drugs (amlodipine, losartan)” to “Blood-pressure-lowering drugs (amlodipine)”.
Issues 10/31/2026 12:05
- 9.2 — Documented interaction omitted: The ER documented interaction “Lisinopril, warfarin, digoxin and metformin with oral semaglutide” (ER line 450, metformin exposure rose 32%, judged not clinically relevant) is missing from caution_items (QRS lines 563-572), although it is not phrased as no interaction found and the parallel rosuvastatin/furosemide entry is listed.
Fixes 10/31/2026 12:05
- 9.2 — Documented interaction omitted: Added “Lisinopril, warfarin, digoxin and metformin with oral semaglutide: higher metformin exposure, judged not clinically relevant” to caution_items, before the rosuvastatin/furosemide entry.
Issues 10/31/2026 12:02
- 4.5 / 9.6 — Repeated wording in cells: action_3_sub at line 478 says “diabetes doses” twice (“Diabetes doses; … between diabetes doses and weight-loss doses”), and the GLP-1 interaction at line 571 says the same thing twice (“avoid; co-use not recommended”).
- 11.4 — Appetite sub mismatches value: time_3 (lines 511–517) pairs “Appetite” / “Days” with “Returns gradually over 5–7 weeks after stopping”, so the sub describes the offset after stopping rather than the ER’s onset (“Appetite falls within days”), and the cell reads as if appetite returns within days.
Fixes 10/31/2026 12:02
- 4.5 / 9.6 — Repeated wording removed: Shortened action_3_sub from “between diabetes doses and weight-loss doses” to “between diabetes and weight-loss doses”, and cut the GLP-1 interaction from “avoid; co-use not recommended” to “avoid”.
- 11.4 — Appetite sub matches onset: Replaced time_3_sub “Returns gradually over 5–7 weeks after stopping” with “Falls within days of starting”, taken from the ER’s “Appetite falls within days”.
Issues 10/31/2026 11:58
- 4.5 — Repeated appetite timing sub: time_3_sub “Appetite falls within days” (line 517) only repeats time_3_label “Appetite” and time_3_value “Days”.
- 7.1 — Use not stated: The opening sentence of at_a_glance (line 439) gives the kind and mechanism but not what semaglutide is used for (diabetes and weight loss, ER Motivation) before the evidence verdict.
- 14.3 — Monitoring targets trimmed: marker_1_target (line 632) drops “percentage” from the ER’s “track percentage change from own baseline”, and marker_2_target (line 643) drops “total” from “track lean-mass share of total weight lost”.
Fixes 10/31/2026 11:58
- 4.5 — Repeated appetite timing sub: Replaced time_3_sub “Appetite falls within days” with “Returns gradually over 5–7 weeks after stopping” (ER Discontinuation & Cycling, Withdrawal effects).
- 7.1 — Use not stated: Opening sentence now reads “Semaglutide is a prescription medication for diabetes and weight loss, a weekly injection or daily tablet copying an appetite-controlling gut hormone.” (ER Motivation); the lede stays at 70 words.
- 14.3 — Monitoring targets trimmed: Restored the ER wording in marker_1_target (“track percentage change from own baseline”) and marker_2_target (“track lean-mass share of total weight lost”).